1. Home
  2. SWIN vs GBIO Comparison

SWIN vs GBIO Comparison

Compare SWIN & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SWIN
  • GBIO
  • Stock Information
  • Founded
  • SWIN 2017
  • GBIO 2016
  • Country
  • SWIN Hong Kong
  • GBIO United States
  • Employees
  • SWIN N/A
  • GBIO N/A
  • Industry
  • SWIN
  • GBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • SWIN
  • GBIO Health Care
  • Exchange
  • SWIN Nasdaq
  • GBIO Nasdaq
  • Market Cap
  • SWIN 214.1M
  • GBIO 29.5M
  • IPO Year
  • SWIN 2023
  • GBIO 2020
  • Fundamental
  • Price
  • SWIN $3.93
  • GBIO $4.51
  • Analyst Decision
  • SWIN
  • GBIO Strong Buy
  • Analyst Count
  • SWIN 0
  • GBIO 4
  • Target Price
  • SWIN N/A
  • GBIO $73.33
  • AVG Volume (30 Days)
  • SWIN 208.1K
  • GBIO 206.6K
  • Earning Date
  • SWIN 08-21-2025
  • GBIO 08-06-2025
  • Dividend Yield
  • SWIN N/A
  • GBIO N/A
  • EPS Growth
  • SWIN N/A
  • GBIO N/A
  • EPS
  • SWIN N/A
  • GBIO N/A
  • Revenue
  • SWIN $3,316,000.00
  • GBIO $24,556,000.00
  • Revenue This Year
  • SWIN $29.79
  • GBIO N/A
  • Revenue Next Year
  • SWIN $54.60
  • GBIO N/A
  • P/E Ratio
  • SWIN N/A
  • GBIO N/A
  • Revenue Growth
  • SWIN N/A
  • GBIO 146.47
  • 52 Week Low
  • SWIN $1.16
  • GBIO $3.00
  • 52 Week High
  • SWIN $4.40
  • GBIO $34.35
  • Technical
  • Relative Strength Index (RSI)
  • SWIN 62.05
  • GBIO 54.72
  • Support Level
  • SWIN $3.70
  • GBIO $4.05
  • Resistance Level
  • SWIN $3.99
  • GBIO $5.10
  • Average True Range (ATR)
  • SWIN 0.35
  • GBIO 0.63
  • MACD
  • SWIN -0.03
  • GBIO 0.02
  • Stochastic Oscillator
  • SWIN 93.02
  • GBIO 35.65

About SWIN Solowin Holdings

Solowin Holdings Ltd is an investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secure one-stop electronic platform. It is engaged in providing securities-related services, investment advisory services, and asset management services to customers. The operations were organized into four reportable segments: Corporate Finance Services, Wealth Management Services, Asset Management Services and Virtual Assets. It derives maximum revenue from Wealth Management Services.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: